My Intelligent Machines’ augmented-intelligence platform reduces the cost, time, and failure rates associated with clinical trials.
With MIMs’ software-as-a-service (SaaS) solution for indication prioritization and biomarker discovery in oncology, you and your team can:
► Access scientific insights to support strategic decisions on indication prioritization at pre-clinical stage
► Increase success rate of clinical trials for new targeted and immune therapies
► Explore new potent combined therapies
► Identify early high-value biomarkers to accelerate companion test development
Predict good responders to new therapies with more than 2X higher performance than other available methodologies
Generate results at one tenth of the cost of consulting services
Complete a month’s work in a single day
Quantify future trial success to attract investment
Move therapies to the clinic faster
► Work code-free in a platform designed for life scientists
► Automate data management and processing
► Empower teams with greater autonomy
► Operate with industry-leading security and compliance
► Wholly own your IP
► Focus on high-value strategic activities
Sound too good to be true? It isn’t.